← Back to Screener
Soligenix, Inc. Common Stock (SNGX)
Price$1.17
Favorite Metrics
Price vs S&P 500 (26W)-40.45%
Price vs S&P 500 (4W)-11.56%
Market Capitalization$11.85M
All Metrics
Book Value / Share (Quarterly)$0.52
P/TBV (Annual)10.22x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-47.39%
Cash Flow / Share (Quarterly)$-1.02
Price vs S&P 500 (YTD)-16.82%
Gross Margin (TTM)8.75%
Net Profit Margin (TTM)-1424.53%
EPS (TTM)$-2.76
10-Day Avg Trading Volume0.16M
EPS Excl Extra (TTM)$-2.76
Revenue Growth (5Y)-51.89%
EPS (Annual)$-2.14
ROI (Annual)-209.37%
Gross Margin (Annual)0.00%
Net Profit Margin (5Y Avg)-2277.89%
Cash / Share (Quarterly)$0.79
ROA (Last FY)-119.98%
EBITD / Share (TTM)$-2.34
ROE (5Y Avg)-248.72%
Operating Margin (TTM)-1574.25%
Cash Flow / Share (Annual)$-1.02
P/B Ratio2.24x
P/B Ratio (Quarterly)2.55x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)7.92x
Net Interest Coverage (TTM)-1725.75x
ROA (TTM)-133.57%
EV / EBITDA (TTM)3.24x
EPS Incl Extra (Annual)$-2.14
Current Ratio (Annual)2.39x
Quick Ratio (Quarterly)2.15x
3-Month Avg Trading Volume0.27M
52-Week Price Return-41.33%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.83
P/S Ratio (Annual)99.29x
Asset Turnover (Annual)0.01x
52-Week High$6.23
Operating Margin (5Y Avg)-2540.96%
EPS Excl Extra (Annual)$-2.14
CapEx CAGR (5Y)-10.08%
Tangible BV CAGR (5Y)6.73%
26-Week Price Return-36.46%
Quick Ratio (Annual)2.15x
13-Week Price Return-16.06%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.39x
Enterprise Value$3.916
Revenue / Share Growth (5Y)-54.25%
Asset Turnover (TTM)0.05x
Book Value / Share Growth (5Y)-12.22%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-7267.90%
Cash / Share (Annual)$0.79
3-Month Return Std Dev49.78%
Gross Margin (5Y Avg)17.76%
Net Income / Employee (TTM)$-1
ROE (Last FY)-209.37%
Net Interest Coverage (Annual)-14.55x
EPS Basic Excl Extra (Annual)$-2.14
P/FCF (TTM)4.33x
Receivables Turnover (TTM)1.39x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.76
Receivables Turnover (Annual)1.39x
ROI (TTM)-248.01%
P/S Ratio (TTM)23.98x
Pretax Margin (5Y Avg)-2441.11%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.83
Price vs S&P 500 (52W)-71.16%
Year-to-Date Return-14.18%
5-Day Price Return0.88%
EPS Normalized (Annual)$-2.14
ROA (5Y Avg)-83.64%
Net Profit Margin (Annual)-6925.17%
Month-to-Date Return-2.54%
Cash Flow / Share (TTM)$-1.38
EBITD / Share (Annual)$-2.28
Operating Margin (Annual)-7907.77%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-130.65%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.76
P/TBV (Quarterly)10.22x
P/B Ratio (Annual)2.55x
Inventory Turnover (TTM)29.64x
Pretax Margin (TTM)-1547.28%
Book Value / Share (Annual)$0.52
Price vs S&P 500 (13W)-16.75%
Beta1.97x
Revenue / Share (TTM)$0.00
ROE (TTM)-248.01%
52-Week Low$1.00
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SNGXSoligenix, Inc. Common Stock | 23.98x | — | 8.75% | — | $1.17 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Soligenix is a biopharmaceutical company developing therapeutics and vaccines for rare diseases and public health threats with unmet medical needs. Operating through Specialized BioTherapeutics and Public Health Solutions segments, the company generates primary revenues from Public Health Solutions, including RiVax (a ricin toxin vaccine candidate), SGX943 (for antibiotic-resistant and emerging infectious diseases), and vaccine research programs targeting Ebola, Marburg, and SARS-CoV-2.